"Does my son have autism?" Robert's mother asked, her voice tight with worry.
As a behavioral and developmental pediatrician with four and a half decades of front-line private practice experience in a Bay Area community, I've encountered this question more times than I can count. Robert's family had come to me as their third stop in a diagnostic odyssey. Two separate specialist teams had already reviewed the case, and both concluded that Robert — a 6-year-old whose name has been changed — did not meet the diagnostic threshold for autism spectrum disorder. What those evaluators did identify was that his intellectual and cognitive functioning lagged roughly two years behind what would be expected for his age — a presentation clinically characterized as global developmental delay. Yet his parents remained determined to obtain an ASD diagnosis. The question worth examining is: why?
Part of the answer lay with the occupational therapist involved in Robert's care. She had formed the clinical impression that his lack of measurable progress might be attributable to an underlying autism diagnosis. Yet her professional standing and the absence of formal psychometric testing meant that neither the school district nor the family's insurer would treat her assessment as actionable. Robert's primary care pediatrician, navigating this diagnostic impasse, ultimately referred the family to my practice.
When I first met Robert alongside his parents, I devoted 45 minutes largely to observing their interactions as a family unit. Within moments of the initial greeting, my clinical instinct suggested that if autism was present at all, it existed at the mildest end of the spectrum. More tellingly, the quality of relational attunement between Robert and his parents — the reciprocal warmth, the responsive engagement — was simply inconsistent with a meaningful ASD diagnosis.
What I observed instead was a child whose communicative and play behaviors were developmentally consistent with those of a typical 4-year-old, not a child of 6. Global developmental delay remained, in my professional judgment, the more clinically precise and accurate characterization of his presentation.
Nevertheless, the diagnostic pressure from the family was palpable. What Robert's parents genuinely needed was for a credentialed specialist to confer an autism diagnosis — not necessarily because they doubted the earlier findings, but because that specific diagnostic label was the gateway through which their insurance carrier would authorize the intervention they sought: applied behavior analysis, or ABA therapy.
During my training fellowship in behavioral and developmental pediatrics at the University of California San Francisco in the late 1970s, the field was experiencing a profound conceptual realignment. The discredited psychoanalytic framework that had blamed so-called "refrigerator mothers" for their children's autism was being displaced by a neurobiological model of the condition. While this paradigm shift rightly absolved parents of unjust culpability and stigma, the prevailing clinical consensus at the time held that autism was both incurable and largely untreatable — a grim prognosis that shaped how clinicians communicated with families.
ASD frequently co-occurs with a constellation of other early developmental challenges — global delay, specific learning disorders, and expressive or receptive language impairments among them. Through the early 1980s, clinicians faced with delivering difficult news to families often emphasized these co-occurring diagnoses rather than leading with an autism label, partly as a means of preserving therapeutic hope and maintaining the parent-child relational bond as a clinical resource.
Against this backdrop, the 1987 publication by Ivar Lovaas at UCLA of his landmark findings on intensive behavioral intervention — what would eventually be formalized as ABA — was initially received with considerable professional skepticism. Lovaas reported that children with clear-cut autism diagnoses, when provided up to 40 hours weekly of structured behavioral therapy beginning at age 2, demonstrated near-typical developmental trajectories and could successfully transition into mainstream kindergarten settings after two years of treatment.
Subsequent research never fully replicated the magnitude of Lovaas's original outcomes, yet a meaningful body of evidence did confirm that ABA produced measurable, positive developmental effects across a range of clinical populations.
The demonstrated efficacy of ABA fundamentally transformed the clinical and cultural landscape surrounding autism. Families of affected children became vocal and politically mobilized advocates for access to these services. Initially, both insurance carriers and public school systems pushed back against covering what was, by any measure, a resource-intensive and costly intervention. Legislative and advocacy pressure eventually compelled coverage — but with a critical structural caveat: eligibility was contingent upon a confirmed ASD diagnosis.
This policy architecture created a powerful diagnostic incentive. Beginning in the late 1990s, parents began approaching clinicians like me with explicit requests for an autism diagnosis specifically to unlock ABA coverage through their insurer or school district. This trend emerged at virtually the same historical moment that reported ASD prevalence rates began their well-documented and dramatic ascent.
What remained largely invisible to the general public — though well understood among developmental specialists — was that ABA's therapeutic benefits extended well beyond the boundaries of ASD. Children with global developmental delay, language disorders, and a range of other early childhood conditions can derive meaningful gains from behavioral intervention. Cognitive and intellectual development in young children is highly responsive to exposure to developmentally appropriate environments and structured learning experiences, regardless of the specific diagnostic etiology.
It is worth underscoring that no intervention is known to accelerate the underlying pace of neurodevelopment itself. All children will acquire new skills over time. Some children with developmental delays will close the gap with their peers; others will continue to progress at a slower trajectory throughout their development.
Where ABA demonstrates particular utility is in addressing the behavioral obstacles that impede learning — dysregulation during transitions, tantrum behavior, and distractibility in the context of frustration. By systematically targeting these behavioral barriers, ABA can meaningfully improve the rate at which affected children acquire new competencies.
In recent years, the neurodiversity-affirming movement within the ASD advocacy community has mounted a substantive challenge to the foundational goals of ABA, which are oriented toward helping the affected individual adapt to and function within conventional social environments. Critics argue that ABA compels autistic individuals to suppress or "mask" their authentic neurological presentation and that the long-term psychological costs outweigh the functional gains.
This critique carries genuine intellectual weight — neurological difference is not inherently pathological, and the spectrum of autistic experience resists any single therapeutic prescription. Yet it is equally true that families of children with moderate to severe functional impairments continue to advocate urgently for access to behavioral intervention.
Robert's parents embodied this reality. Like countless families navigating similar circumstances, they were not willing to leave any therapeutic avenue unexplored. The financial arithmetic, however, was crushing: a full year of ABA at 30 hours per week carried an estimated out-of-pocket cost approaching $70,000 — a figure simply beyond the family's means. Their hope, therefore, was that yet another specialist consultation might yield the diagnostic determination that had eluded them. Robert's family is far from unique; tens of thousands of households across the country face structurally identical situations.
Reported rates of intellectual developmental delay in children have declined in recent years in a pattern that inversely mirrors the rise in ASD diagnoses. Notably, nearly half of children who had received community-based ASD diagnoses and were recruited for an MRI research study did not meet diagnostic criteria when formally evaluated by academic clinicians. The prevailing explanations for the surge in ASD prevalence center on broadened diagnostic criteria and heightened clinical and public awareness. A minority of commentators, dismissing an extensive body of scientific evidence to the contrary, continue to attribute the increase to vaccines or common analgesics.
What has received strikingly little attention in these discussions, however, is the economic architecture underpinning the diagnostic surge.
When I asked Robert's parents to articulate specifically what was driving their urgency around ABA, they described feeling profoundly uncertain about how to support their son's development. When I pressed further — asking what particular behaviors or challenges were causing them the most day-to-day distress — it emerged that Robert's most disruptive presentations involved intense emotional dysregulation during routine transitions and significant resistance to parental limit-setting. Having observed the family's interaction patterns directly, I proposed an alternative path: a collaborative, individualized approach to developing parenting strategies calibrated to Robert's developmental stage and specific temperamental profile. The parents responded positively to this framing, and the urgency around the diagnostic question seemed, at least temporarily, to recede.
Two weeks later, however, they informed me that they intended to pursue a fourth specialist evaluation — driven entirely by the financial and service access benefits that an autism diagnosis would confer. I believed they were operating under a flawed assumption: that ABA represented the only viable pathway to meaningful progress for their son.
The structural problem is that insurance coverage frameworks are built around discrete medical diagnoses. The only durable solution to the diagnostic pressure families like Robert's experience is the creation of equitable funding mechanisms and service access for all developmental conditions affecting young children — not just those that carry an ASD label. In the current U.S. policy environment, that prospect remains remote.
There is a further irony embedded in this story. The clinical outcomes of ABA, measured across decades of practice, have grown less robust as the broader parenting culture has evolved and as some of the more rigidly structured early Lovaas protocols — characterized by critics as resembling a form of behavioral boot camp — have been substantially modified and softened.
Yet the institutional momentum behind ABA access and the concurrent escalation of ASD diagnosis rates carry an undeniable economic dimension that has gone largely unexamined in public discourse. For those genuinely seeking to understand the forces behind the ASD prevalence explosion, the analytical framework is straightforward: follow the money.
Lawrence Diller, M.D., practices behavioral/developmental pediatrics in Walnut Creek, Calif. He is the author of several books on child behavior and psychiatric drugs.